Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the market of vascular interventional surgery robots. It is reported that behind this "new" company are years of scientific research and technical precipitation-that is, the research and development accumulation of the founding team led by Academician Guo Shuxiang and Dr. Guo Jian for nearly 30 years, and the corresponding patent matrix.
It is reported that as early as 2008, the founder of the company, Academician Guo Shuxiang, took the lead in developing the world's first panvascular interventional surgery robot in Japan, which can be used for angiography and the treatment of nerves, coronary arteries and peripheral blood vessels; In 20 17, the prototype of vascular interventional surgery robot developed by the company team completed the first clinical trial of nerve interventional surgery in Beijing Tiantan Hospital. So far, the vascular interventional surgery robot of ABO Medical Robot has been iterated to the third generation.
According to the person in charge of Aibo Medical Robot, the company's vascular interventional surgery robot is improving in the direction of miniaturization, light weight and low cost. This year, ABO Medical Robot's vascular interventional surgery robot is expected to enter the registered clinical stage.
In recent years, the number of vascular interventional operations in China has increased, which has gradually exposed problems such as shortage of medical resources and uneven distribution of doctors and patients. Taking nerve intervention as an example, nerve intervention is called the jewel in the crown of interventional surgery, which has the characteristics of great difficulty, high risk and long time. The cerebral vessels are fragile, and the precision of interventional surgery is high, which is highly dependent on the personal experience and level of doctors. The time required for a nerve intervention operation may be more than twice as long as that for a coronary intervention operation. The training period of doctors is long and the corresponding workload is heavy. The emergence of surgical robots makes it possible for vascular interventional surgery to be intelligent and automatic, acting as doctors' eyes, hands and brain.
Based on the huge market demand, the market scale of vascular interventional surgery robots in China will reach 34 million yuan in 2022, and further increase to 5.824 billion yuan in 2030, with a compound annual growth rate of 90.3% from 2022 to 2030.
The person in charge of Aibo Medical Robot said: "Compared with laparoscopy or orthopedics, vascular intervention is an easier and more automated surgical scene. Vascular interventional surgery robots operate in blood vessels, just like self-driving cars driving on highways. " It is reported that through the mode of master-slave separation, based on accurate force feedback, medical staff can use ABO medical robot's vascular interventional surgery robot to perform surgery outside the catheter, which not only makes interventional surgery more accurate and efficient, but also reduces the incidence of postoperative complications of patients, keeps doctors away from the catheter room and reduces radiation.
According to reports, at present, most vascular interventional surgical robots on the market have a single function and can only meet the function of pushing guide wires. However, in vascular interventional surgery, especially in neurointerventional surgery, doctors usually need to operate a variety of guidewire catheters for surgery, and during the operation, they need to operate catheters for multiple angiography to observe the positions of instruments and blood vessels. Due to the inability to realize the cooperative operation of various instruments, the existing vascular interventional surgery robots are not widely compatible with all kinds of vascular interventional surgery, including angiography and treatment, and play a role in surgery for a short time. At the same time, they need bedside teamwork, so doctors can't really avoid exposure to radiation.
Therefore, ABO Medical Robot has designed a vascular interventional surgery robot based on the modular concept, which can meet the cooperative operation control of multi-catheter guide wires and complete composite actions such as pushing, rotating, pushing+rotating. This product is compatible with all kinds of standardized guide wires in the market, and is suitable for all kinds of surgical operations, including nerve intervention, coronary intervention, peripheral intervention, etc., and can be regarded as a "panvascular interventional surgical robot". It is reported that these operations "will involve more than 5 million domestic operations in the future". At present, Aibo Medical Robot has established close cooperation with well-known hospitals such as Shanghai Changhai Hospital, Shanghai Zhongshan Hospital, Huazhong University of Science and Technology, Shenzhen Hospital, etc., and wants to find the real pain points and needs in clinic through the mode of combining doctors with workers.
From the supply side, the global vascular interventional surgery robot market is still in the early stage of development. At present, only three products have been approved, and none of the domestic vascular interventional surgery robots have been approved, which has a certain market access window. Nowadays, a number of innovative enterprises at home and abroad have begun to flood into the robot track of vascular interventional surgery, such as Weimai Medical, Aopeng Medical, Minimally Invasive Robot and Ruixin Medical. , began to spell technology, team, product. Unlike the endoscopic surgery robot market where Leonardo da Vinci's surgical robots occupy half of the country, the market pattern of vascular interventional surgery robots is uncertain.
202 1 year, attracting nearly 10 billion funds. Is vascular intervention the next dark horse of surgical robot? | 36Kr new wind direction